Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Determination and characterization of a cannabinoid receptor in rat brain.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Roche reports positive studies of MabThera given by subcutaneous injection
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Amiloride: a molecular probe of sodium transport in tissues and cells.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Assessment of statistical significance and clinical relevance.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Treatment of acute transverse myelitis and its early complications.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
[Nicolau syndrome after administration of glatiramer acetate].

Pages